Travere Therapeutics, Inc.NASDAQ: TVTX

Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

· Issued by Travere Therapeutics, Inc.

Sparsentan treatment group experienced 49.8 percent mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator; interim primary efficacy endpoint achieved, p

Travere Therapeutics, Inc. on 6ix

Story so far

Earlier from Travere Therapeutics

Later from Travere Therapeutics

All Travere Therapeutics news releases